Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

COVID-19 blood-thinner trials and LY-CoV555 trials paused for futility

By Brian Buntz | December 23, 2020

coronavirus COVID-19 Pfizer

[Photo by Fusion Medical Animation on Unsplash]

NIH has paused enrollment in three clinical trials for COVID-19 patients taking full doses of anticoagulants. The studies found that, for COVID-19 patients requiring intensive care unit support, anticoagulants did not reduce their need for organ support. Independent boards overseeing the trials could not rule out the potential for harm for such patients taking anticoagulants. 

The studies, which include the REMAP-CAP, ACTIV-4 and ATTACC trials, will continue testing high doses of anticoagulants in moderately ill hospitalized COVID-19 patients, according to an NIH statement. 

A related trial, ACTIV-3, was halted for futility for patients taking the neutralizing monoclonal antibody, LY-CoV555 (bamlanivimab) from Eli Lilly (NYSE:LLY). That study administered the drug in conjunction with remdesivir for hospitalized COVID-19 patients without end-organ failure, according to Physician’s Weekly. 

Prior research related to LY-CoV555 associated the antibody with reduced viral load, hospitalizations and emergency department visits for COVID-19 patients. The product received emergency use authorization from the FDA in November. 

The NIH statement stressed that anticoagulants still offer potential for COVID-19 patients. Some hospitals have aggressively used anticoagulants to treat critically ill COVID-19 patients. Because the virus can trigger inflammation and blood clots, blood thinners could prevent related adverse events such as stroke, heart attack and lung failure.  

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Sandoz Logo 2025
Sandoz breaks ground on biosimilar plant in Slovenia
Nymi Logo_2022 (1)
Nymi, Caliber partner on passwordless authentication for pharma manufacturing
Moving toward the autonomous lab and what’s possible today
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE